The Impact of FDA’s Draft Guidance for Oncology Patient-Reported Outcomes

Signant’s in-house experts discuss the key takeaways from the FDA’s recent guidance on the use of patient-reported outcomes (PROs) in oncology clinical trials, including the recommended measures and frequency in administration. Readers will also learn the core domains that the agency values the most when reviewing oncology PROM data.